Nonketotic hyperglycinemia, usually called NKH, is a rare inherited metabolic disorder in which the body cannot properly break down the amino acid glycine, leading to dangerously high levels of glycine in the brain, spinal fluid, and blood. The condition primarily affects newborns and can cause seizures, severe muscle weakness, breathing problems, and profound developmental disability. Because it stems from genetic defects in the enzyme system responsible for glycine metabolism, there is currently no cure, and the treatments available are limited in what they can achieve. Still, the severity varies more than many parents are initially told, and research into gene therapy has recently produced striking results in animal models.
What Goes Wrong in NKH
Glycine is one of the simplest amino acids and is normally present throughout the body. A set of enzymes in the mitochondria, collectively called the glycine cleavage system, is responsible for breaking glycine down. In NKH, this system does not work properly because of mutations in the genes that encode its components. Three genes are involved: GLDC, AMT, and GCSH.1PubMed. Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia About 80% of people with classic NKH have mutations in GLDC, the gene encoding the largest protein in the system. In a large genetic study of 578 families, researchers identified 410 unique mutations across these genes, and sequencing found the disease-causing mutations on both copies of the gene in 98% of cases.2Genetics in Medicine. The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT
When the glycine cleavage system fails, glycine piles up in body fluids, especially in the brain and cerebrospinal fluid (CSF).3PubMed. The relation of cerebrospinal fluid and plasma glycine levels in propionic acidaemia, a ‘ketotic hyperglycinaemia’ Because glycine acts on certain receptors in the brain, particularly the NMDA-type glutamate receptor, the excess glycine can overstimulate brain cells, causing the seizures and neurological damage seen in affected infants.4PubMed. The Role of Excitotoxicity, Oxidative Stress and Bioenergetics Disruption in the Neuropathology of Nonketotic Hyperglycinemia Glycine also activates a separate, inhibitory receptor type in the brainstem, which is thought to explain the breathing problems and extreme floppiness many newborns with NKH experience. These two receptor pathways mean that excess glycine can simultaneously cause overexcitation in some brain regions and excessive inhibition in others.5Pediatric Neurology. Nonketotic hyperglycinemia: Treatment with NMDA antagonist and consideration of neuropathogenesis
How NKH Presents in Newborns
The most common form is neonatal NKH, in which symptoms appear within the first few days of life. The hallmark presentation is a baby who becomes increasingly lethargic and floppy, often within 24 to 48 hours of birth. Feeding becomes difficult or impossible, seizures begin, and in many cases the infant develops apnea, meaning they stop breathing on their own.6PubMed Central. Neonatal Nonketotic Hyperglycinemia: A Rare Case from Pakistan In severe cases, prenatal clues can sometimes be present, including excessive amniotic fluid and rhythmic hiccup-like fetal movements.7PubMed Central. Neonatal Nonketotic Hyperglycinemia: A Severe Case With Prenatal Indicators and Comprehensive Review of Recognition and Management
Within the neonatal form, severity falls on a spectrum. The severe end, which is the most common presentation, typically means intractable epilepsy and little to no developmental progress. But there is also an attenuated form in which children may achieve some developmental milestones, though they generally still have intellectual disability and seizures. A study that tried to distinguish these two trajectories found that symptom onset before three months of age and a CSF-to-plasma glycine ratio above 0.15 are strong indicators of the severe form, while later onset and a lower ratio point toward attenuated disease.8PubMed. Integrative Approach to Predict Severity in Nonketotic Hyperglycinemia That distinction matters enormously for families making care decisions.
Late-Onset and Transient Forms
NKH is not exclusively a newborn disease. There are four recognized disease types: neonatal, infantile, late-onset, and transient.9J-STAGE / Proceedings of the Japan Academy, Series B. Nonketotic hyperglycinemia: Pathophysiological studies Late-onset NKH can show up in childhood rather than infancy. One reported case involved a girl who was apparently healthy until age five, when a fever triggered involuntary movements, unsteadiness, and altered consciousness. Genetic testing found a single heterozygous mutation in GLDC, suggesting that even carrying one mutant copy of the gene can sometimes produce symptoms under stress.10PubMed. Late-onset nonketotic hyperglycinemia with a heterozygous novel point mutation of the GLDC gene The genetics of late-onset and transient NKH remain poorly understood compared to the neonatal form.
Transient NKH looks biochemically identical to the classic form in the early days: high glycine in plasma and CSF, the same devastating neurological presentation. But in transient NKH, the glycine abnormalities gradually resolve over days to months. This is critical because outcomes are dramatically different. Most children with the transient form go on to develop normally, while nearly all children with classic NKH survive with serious neurological damage.11PubMed Central. Transient nonketotic hyperglycinemia: two case reports and literature review The trouble is that in the acute phase it can be nearly impossible to tell the two apart, making early counseling for families agonizing. Serial biochemical testing over weeks is typically needed to differentiate them.
The Attenuated Form and Psychiatric Symptoms
Children with attenuated NKH occupy a middle ground that often catches families and even doctors off guard. These children may learn to walk and speak, sometimes attending special-education programs, but they face persistent challenges including seizures, learning difficulties, and behavioral issues. One finding that stands out from clinical research is that psychiatric problems occur predominantly in the attenuated form rather than the severe form.12PubMed. Integrative Approach to Predict Severity in Nonketotic Hyperglycinemia This makes intuitive sense: children with severe NKH often have such profound impairment that typical psychiatric diagnoses do not apply, whereas those with enough cognitive function to interact socially may develop anxiety, behavioral outbursts, or attention problems.
Because attenuated NKH allows greater developmental progress, the stakes of early and aggressive treatment are arguably highest in this group. A study comparing siblings who shared the same genetic mutations but were diagnosed and treated at different ages found a clear advantage for the sibling treated from the newborn period. In each pair, the sibling who received early treatment with both sodium benzoate and dextromethorphan achieved more developmental milestones and scored higher on developmental assessments.13PubMed. Neurodevelopmental Outcome and Treatment Efficacy of Benzoate and Dextromethorphan in Siblings with Attenuated Nonketotic Hyperglycinemia The lesson is that in attenuated disease, treatment intensity and timing genuinely matter.
Why Standard Newborn Screening Misses NKH
One of the cruelest aspects of NKH is that standard newborn screening programs in most countries do not reliably detect it. In a large screening effort that tested over 733,000 babies, nine were later diagnosed with NKH, but only two had glycine levels above the screening cutoff at birth. The remaining seven could not have been identified without triggering an unacceptably high rate of false positives in healthy babies.14PubMed. Diagnosis of Non-Ketotic Hyperglycinemia by MSMS newborn screening might benefit patients with post-neonatal presentation The problem is that glycine levels in a newborn blood spot overlap too much between healthy and affected babies to draw a clean line.
In practice, NKH is usually diagnosed after symptoms appear, when a doctor orders amino acid levels in the blood and cerebrospinal fluid. A high CSF-to-plasma glycine ratio is the classic biochemical indicator. Brain imaging with a specialized technique called proton MR spectroscopy can also detect elevated glycine in the brain non-invasively and can be useful for monitoring how a patient responds to treatment.15PubMed Central. Localized proton MR spectroscopic detection of nonketotic hyperglycinemia in an infant Genetic testing then confirms the diagnosis and helps predict severity.
Current Treatment and Its Limits
Treatment for NKH is based on two strategies: lowering glycine levels and blocking the harmful effects of excess glycine on the brain. Sodium benzoate is the main drug used to reduce glycine. It works by binding to glycine in the body and creating a compound that is excreted in urine, effectively pulling glycine out of circulation. High-dose benzoate treatment that brings plasma glycine levels toward normal has been shown to reduce seizures and increase alertness.16PubMed. Benzoate treatment and the glycine index in nonketotic hyperglycinaemia
The second strategy has traditionally involved NMDA receptor antagonists, specifically dextromethorphan (an ingredient commonly found in cough medicine) or ketamine. The reasoning was straightforward: if excess glycine overstimulates NMDA receptors, blocking those receptors should reduce brain damage.17PubMed Central. Nonketotic Hyperglycinemia: Insight into Current Therapies For decades, this was the accepted rationale, and many treatment protocols still include one of these drugs.
That logic has recently come under serious scrutiny. It turns out that the same NMDA receptors activated by glycine also have an alternative activator, a molecule called D-serine, which is markedly decreased in NKH. This means the receptors may actually be underactivated in some contexts rather than overactivated, which would make blocking them with an antagonist counterproductive. A 2024 reassessment concluded that clear clinical evidence of added benefit from dextromethorphan or ketamine beyond what glycine-lowering alone achieves has not been documented, and recommended that their routine use be reevaluated, especially given emerging concerns about adverse effects.18PubMed. The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment This is a significant shift in thinking for a condition with so few treatment options.
Even with the best available therapy, outcomes in severe NKH remain poor. Children with the severe form typically make little or no developmental progress and have epilepsy that resists most medications.19PubMed Central. Nonketotic Hyperglycinemia: Insight into Current Therapies Some families ultimately choose palliative or comfort-focused care when the severity becomes clear. For the attenuated form, treatment can meaningfully change the trajectory, but no current therapy restores normal development.
Gene Therapy Research
Because NKH is caused by the loss of a single enzyme’s function, it is a natural candidate for gene therapy, which aims to deliver a working copy of the defective gene directly into cells. Several research groups have been testing this approach in mouse models of the disease, and the results have been encouraging enough to generate real optimism in the NKH community.
One study used an AAV9-based viral vector, a harmless modified virus designed to carry genes into cells, to deliver a working copy of GLDC into mice that lack the enzyme. The treatment was given shortly after birth. Treated mice showed restored GLDC protein in their cells, significantly lower glycine levels in both plasma and brain tissue, and normalization of folate metabolism, which is also disrupted in NKH because the glycine cleavage system feeds into one-carbon metabolism pathways.20PubMed. AAV-mediated expression of mouse or human GLDC normalises metabolic biomarkers in a GLDC-deficient mouse model of Non-Ketotic Hyperglycinemia
A more recent study went further by testing the approach in mice engineered to carry a human clinical mutation, making the model more relevant to patients. A single injection of the gene therapy vector boosted the growth of a brain cell type called astrocytes without triggering inflammation, and conferred complete protection against disease progression and death in the treated mice.21bioRxiv. Gene therapy prevents disease and death from non-ketotic hyperglycinemia That 100% survival figure in a model that otherwise shows high mortality is remarkable, though mouse results do not automatically translate to humans. The jump from a controlled animal study to a safe, effective treatment for children involves many steps: manufacturing, dosing, safety testing, and clinical trials that will take years. Still, for a condition that currently has no way to fix the underlying defect, these findings represent a genuine shift from purely symptom-based management toward the possibility of addressing the root cause.
Variant Forms With Overlapping Symptoms
Not every case of elevated glycine with seizures is classic NKH. Some patients have mutations not in the three glycine cleavage genes but in genes involved in producing lipoic acid, a cofactor that the glycine cleavage system depends on to function. Mutations in LIAS, for instance, cause a variant form of NKH combined with defects in mitochondrial energy metabolism, leading to a more complex picture that includes encephalopathy and heart muscle disease alongside the glycine accumulation.22PubMed. Lipoic acid biosynthesis defects
Similarly, mutations in GCSH, which encodes the so-called H-protein in the glycine cleavage system, produce a broader syndrome because the H-protein has a dual role. It participates in glycine breakdown but is also required for lipoylation, a chemical modification essential for other energy-producing enzymes like pyruvate dehydrogenase. Patients with GCSH mutations can therefore present with a combined deficiency affecting both glycine metabolism and cellular energy production. The clinical range is wide, from fatal neonatal disease to milder presentations with developmental delay, behavioral problems, and movement disorders.23PubMed Central. Pathogenic variants in GCSH encoding the moonlighting H-protein cause combined nonketotic hyperglycinemia and lipoate deficiency These variant forms matter for families because the treatment implications and prognosis differ from classic NKH, and genetic testing is the only way to sort them out.
Reproductive Planning for Carrier Families
NKH follows an autosomal recessive inheritance pattern, meaning both parents must carry one defective copy of the gene for a child to be affected. Each pregnancy between two carriers has a one-in-four chance of producing an affected child. For families who already have a child with NKH, the question of future pregnancies is understandably weighty.
Preimplantation genetic diagnosis, or PGD, is one option. This involves creating embryos through in vitro fertilization, testing each embryo for the family’s known mutation, and transferring only unaffected embryos. The first successful PGD case for NKH was reported in a family carrying a GLDC deletion, resulting in the birth of a healthy child whose status was confirmed after birth.24PubMed. Delivery of a normal baby after preimplantation genetic diagnosis for non-ketotic hyperglycinaemia Prenatal testing through amniocentesis or chorionic villus sampling is also available once the mutations in a family are known. Carrier testing for extended family members is straightforward once a genetic diagnosis has been established in the affected child. These options do not help the child already diagnosed, but they give families a measure of control over future pregnancies that can be profoundly meaningful after the shock of an NKH diagnosis.
The Genetic Landscape Is More Complicated Than It Looks
A common misconception is that NKH is a single disease with a single mutation. In reality, the genetic picture is extraordinarily diverse. In the large study of 578 families, researchers found 410 different mutations, with 246 of them never described before.25Genetics in Medicine. The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT Most mutations in GLDC are “private,” meaning they occur in only one or a few families worldwide. Some are point mutations that change a single amino acid in the protein. Others involve deletions of entire chunks of DNA, and the locations of these deletions correlate with structural features of the gene, particularly the size of non-coding regions and the presence of repetitive DNA elements.
This genetic diversity is part of why predicting severity from genetics alone remains imperfect. Mutations that leave the enzyme with some residual activity tend to produce attenuated disease, while those that completely abolish function lead to the severe form. But the relationship is not always clean, and two children with the same mutation pair can occasionally follow different clinical paths. Researchers have tried combining genetic data with biochemical markers like CSF glycine levels and clinical onset age to build more reliable prediction models, and these integrative approaches outperform any single marker on its own.26PubMed. Integrative Approach to Predict Severity in Nonketotic Hyperglycinemia For families awaiting a prognosis, this means that the genetic report is only one piece of the puzzle, and doctors increasingly look at the full picture before committing to predictions about a child’s future.